Molecular Analysis of 150 Lung Adenocarcinoma

NCT02843711 | Unknown

• 1 other identifier: 69HCL15_0161
• Study Type: observational
• Target: 152
• Locations: 1 country
• Sites: 1

Brief Summary

LUNG-EST is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at Hospices civils de Lyon and with a diagnosis of lung adenocarcinomas. For all patients, clinical data and histopathological data are available. The objective of this study is to characterize these lung adenocarcinomas by the LungCarta Panel using the mass spectrometry array Sequenom. This panel could identify 214 DNA mutations and/or frameshift insert/deletion among 26 oncogenes. Once included in the study, the adenocarcinomas are also included in a Tissue MicroArray (TMA) in order to perform immunohistochemical analysis. Immunohistochemical staining with innovative antibodies are correlated with clinical, histopathological and molecular data. Our hypothesis is that this TMA could constitute a good tool to screen interesting protein's expression.

Conditions

Lung Adenocarcinoma

Keywords

Lungcarta Panel; lung adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• Genomic DNA Mutation

  Mutations identified by the LungCarta Panel (Sequenom) at the time of diagnosis. DNA was extracted from the lung surgical specimen.

  at diagnosis (Day 0)

Study Arms (1)

Adenocarcinoma

Tumour samples coming from patients harboring a lung adenocarcinoma diagnosed at the Hospices Civils de Lyon. Tumour samples are coming from lung surgery.

Genetic: Sequencing

Interventions

Sequencing GENETIC

Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.

Adenocarcinoma

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Adults\>18 years old with diagnosis of lung adenocarcinoma and treatment by surgery

You may qualify if:

• Adults
• lung adenocarcinoma
• Surgical specimen

You may not qualify if:

• not adenocarcinoma subtype of lung cancer
• Tumour biopsy
• insufficient material for DNA extraction

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Anatomie et cytologie pathologiques Groupement hospitalier Est, Institut de cancérologie des Hospices civils de Lyon,

Lyon, 69008, France

Location

Biospecimen

Retention: SAMPLES WITH DNA

Paraffin-embedded formalin fixed tumour sample

MeSH Terms

Conditions

Adenocarcinoma of Lung

Interventions

Base Sequence

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site

Intervention Hierarchy (Ancestors)

Molecular Structure; Biochemical Phenomena; Chemical Phenomena; Genetic Structures; Genetic Phenomena

Study Officials

• Marie BREVET, MD

  Hospices Civils de Lyon

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 20, 2016
• First Posted: July 26, 2016
• Study Start: January 1, 2014
• Primary Completion: January 1, 2016
• Study Completion: December 1, 2017
• Last Updated: July 26, 2016

Record last verified: 2016-07

Locations

FR (1)